Q4 device financing reached $902 million versus Q3’s $734 million, while device M&A dollar volume increased $19 billion, from Q3’s $4.9 billion. Diagnostics companies raised $750 million, an 85% rise over the previous quarter’s $405 million; although diagnostics M&A totaled just $1 billion, it was the most deal-active quarter of 2014 with 11 transactions.
Device companies finished 2014 raising $902 million during the fourth quarter, bringing the full-year financing total to $4 billion, remaining exactly flat from 2013's figure. (See Exhibit 1.) Once again, late-stage venture rounds were the dominating source of funding, together representing $1.1 billion of the $4 billion. But IPOs made a huge comeback, one that we started to see in Q4 2013.
Exhibit 1
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
